Last reviewed · How we verify
Sunitinib, Pemetrexed
At a glance
| Generic name | Sunitinib, Pemetrexed |
|---|---|
| Also known as | Sutent, SU011248, Alimta |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pan Tumor Rollover Study (PHASE2)
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (PHASE3)
- Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer (PHASE2)
- Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen (PHASE2)
- A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors (PHASE1)
- A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sunitinib, Pemetrexed CI brief — competitive landscape report
- Sunitinib, Pemetrexed updates RSS · CI watch RSS
- Pfizer portfolio CI